VEGF-C Promotes Immune Tolerance in B16 Melanomas and Cross-Presentation of Tumor Antigen by Lymph Node Lymphatics

Cell Reports

Volumn 1, Issue 3, 2012, Pages 191-199

  Lund, Amanda W ^a   Duraes, Fernanda V ^b   Hirosue, Sachiko ^a   Raghavan, Vidya R ^a   Nembrini, Chiara ^a   Thomas, Susan N ^a   Issa, Amine ^a   Hugues, Stéphanie ^b   Swartz, Melody A ^a  

^a EPFL   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN; VASCULOTROPIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CROSS PRESENTATION; ENDOTHELIUM CELL; IMMUNOLOGICAL TOLERANCE; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MELANOMA B16; MOUSE; NONHUMAN; PROTEIN FUNCTION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; APOPTOSIS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; DENDRITIC CELLS; ENDOTHELIAL CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNE TOLERANCE; LYMPH NODES; LYMPHANGIOGENESIS; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; PEPTIDES; STROMAL CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

MURINAE; MUS;

EID: 84861116064     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2012.01.005     Document Type: Article

References (43)

1. Anichini A., Vegetti C., Mortarini R. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol. Immunother. 2004, 53:855-864.
2. + T cells in metastases from melanoma patients. J. Clin. Invest. 2011, 121:2350-2360.
3. Clement C.C., Cannizzo E.S., Nastke M.D., Sahu R., Olszewski W., Miller N.E., Stern L.J., Santambrogio L. An expanded self-antigen peptidome is carried by the human lymph as compared to the plasma. PLoS ONE 2010, 5:e9863.
4. Clement C.C., Rotzschke O., Santambrogio L. The lymph as a pool of self-antigens. Trends Immunol. 2011, 32:6-11.
5. Cohen J.N., Guidi C.J., Tewalt E.F., Qiao H., Rouhani S.J., Ruddell A., Farr A.G., Tung K.S., Engelhard V.H. Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. J. Exp. Med. 2010, 207:681-688.
6. DuFort C.C., Paszek M.J., Weaver V.M. Balancing forces: architectural control of mechanotransduction. Nat. Rev. Mol. Cell Biol. 2011, 12:308-319.
7. Ferguson A.R., Nichols L.A., Zarling A.L., Thompson E.D., Brinkman C.C., Hargadon K.M., Bullock T.N., Engelhard V.H. Strategies and challenges in eliciting immunity to melanoma. Immunol. Rev. 2008, 222:28-42.
8. Fletcher A.L., Lukacs-Kornek V., Reynoso E.D., Pinner S.E., Bellemare-Pelletier A., Curry M.S., Collier A.R., Boyd R.L., Turley S.J. Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. J. Exp. Med. 2010, 207:689-697.
9. Fleury M.E., Boardman K.C., Swartz M.A. Autologous morphogen gradients by subtle interstitial flow and matrix interactions. Biophys. J. 2006, 91:113-121.
10. Förster R., Davalos-Misslitz A.C., Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat. Rev. Immunol. 2008, 8:362-371.
11. Friedlaender M.H., Baer H. Immunologic tolerance: role of the regional lymph node. Science 1972, 176:312-314.
12. Harrell M.I., Iritani B.M., Ruddell A. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am. J. Pathol. 2007, 170:774-786.
13. He Y., Kozaki K., Karpanen T., Koshikawa K., Yla-Herttuala S., Takahashi T., Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst. 2002, 94:819-825.
14. Hirosue S., Kourtis I.C., van der Vlies A.J., Hubbell J.A., Swartz M.A. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine 2010, 28:7897-7906.
15. Issa A., Le T.X., Shoushtari A.N., Shields J.D., Swartz M.A. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res. 2009, 69:349-357.
16. Kataru R.P., Kim H., Jang C., Choi D.K., Koh B.I., Kim M., Gollamudi S., Kim Y.K., Lee S.H., Koh G.Y. T lymphocytes negatively regulate lymph node lymphatic vessel formation. Immunity 2011, 34:96-107.
17. Kerjaschki D., Bago-Horvath Z., Rudas M., Sexl V., Schneckenleithner C., Wolbank S., Bartel G., Krieger S., Kalt R., Hantusch B., et al. Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J. Clin. Invest. 2011, 121:2000-2012.
18. Kluger M.S., Colegio O.R. Lymphangiogenesis linked to VEGF-C from tumor-associated macrophages: accomplices to metastasis by cutaneous squamous cell carcinoma?. J. Invest. Dermatol. 2011, 131:17-19.
19. Liao S., Cheng G., Conner D.A., Huang Y., Kucherlapati R.S., Munn L.L., Ruddle N.H., Jain R.K., Fukumura D., Padera T.P. Impaired lymphatic contraction associated with immunosuppression. Proc. Natl. Acad. Sci. USA 2011, 108:18784-18789.
20. Lukacs-Kornek V., Malhotra D., Fletcher A.L., Acton S.E., Elpek K.G., Tayalia P., Collier A.R., Turley S.J. Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes. Nat. Immunol. 2011, 12:1096-1104.
21. Lund A.W., Swartz M.A. Role of lymphatic vessels in tumor immunity: passive conduits or active participants?. J. Mammary Gland Biol. Neoplasia 2010, 15:341-352.
22. Mandriota S.J., Jussila L., Jeltsch M., Compagni A., Baetens D., Prevo R., Banerji S., Huarte J., Montesano R., Jackson D.G., et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001, 20:672-682.
23. Miteva D.O., Rutkowski J.M., Dixon J.B., Kilarski W., Shields J.D., Swartz M.A. Transmural flow modulates cell and fluid transport functions of lymphatic endothelium. Circ. Res. 2010, 106:920-931.
24. Munn D.H., Mellor A.L. The tumor-draining lymph node as an immune-privileged site. Immunol. Rev. 2006, 213:146-158.
25. Padera T.P., Kadambi A., di Tomaso E., Carreira C.M., Brown E.B., Boucher Y., Choi N.C., Mathisen D., Wain J., Mark E.J., et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886.
26. Peinado H., Lavotshkin S., Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 2011, 21:139-146.
27. Randolph G.J., Angeli V., Swartz M.A. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 2005, 5:617-628.
28. Reynoso E.D., Lee J.W., Turley S.J. Peripheral tolerance induction by lymph node stroma. Adv. Exp. Med. Biol. 2009, 633:113-127.
29. Roberts N., Kloos B., Cassella M., Podgrabinska S., Persaud K., Wu Y., Pytowski B., Skobe M. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 2006, 66:2650-2657.
30. Schurich A., Berg M., Stabenow D., Böttcher J., Kern M., Schild H.J., Kurts C., Schuette V., Burgdorf S., Diehl L., et al. Dynamic regulation of CD8 T cell tolerance induction by liver sinusoidal endothelial cells. J. Immunol. 2010, 184:4107-4114.
31. Shieh A.C., Rozansky H.A., Hinz B., Swartz M.A. Tumor cell invasion is promoted by interstitial flow-induced matrix priming by stromal fibroblasts. Cancer Res. 2011, 71:790-800.
32. Shields J.D., Fleury M.E., Yong C., Tomei A.A., Randolph G.J., Swartz M.A. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 2007, 11:526-538.
33. Shields J.D., Kourtis I.C., Tomei A.A., Roberts J.M., Swartz M.A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010, 328:749-752.
34. Sixt M., Kanazawa N., Selg M., Samson T., Roos G., Reinhardt D.P., Pabst R., Lutz M.B., Sorokin L. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 2005, 22:19-29.
35. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., Riccardi L., Alitalo K., Claffey K., Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 2001, 7:192-198.
36. Tammela T., Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell 2010, 140:460-476.
37. Thaunat O., Patey N., Caligiuri G., Gautreau C., Mamani-Matsuda M., Mekki Y., Dieu-Nosjean M.C., Eberl G., Ecochard R., Michel J.B., et al. Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis. J. Immunol. 2010, 185:717-728.
38. Thompson E.D., Enriquez H.L., Fu Y.X., Engelhard V.H. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J. Exp. Med. 2010, 207:1791-1804.
39. Turley S.J., Fletcher A.L., Elpek K.G. The stromal and haematopoietic antigen-presenting cells that reside in secondary lymphoid organs. Nat. Rev. Immunol. 2010, 10:813-825.
40. von Oppen N., Schurich A., Hegenbarth S., Stabenow D., Tolba R., Weiskirchen R., Geerts A., Kolanus W., Knolle P., Diehl L. Systemic antigen cross-presented by liver sinusoidal endothelial cells induces liver-specific CD8 T-cell retention and tolerization. Hepatology 2009, 49:1664-1672.
41. Wong S.Y., Haack H., Crowley D., Barry M., Bronson R.T., Hynes R.O. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res. 2005, 65:9789-9798.
42. Yanai Y., Furuhata T., Kimura Y., Yamaguchi K., Yasoshima T., Mitaka T., Mochizuki Y., Hirata K. Vascular endothelial growth factor C promotes human gastric carcinoma lymph node metastasis in mice. J. Exp. Clin. Cancer Res. 2001, 20:419-428.
43. Zippelius A., Batard P., Rubio-Godoy V., Bioley G., Liénard D., Lejeune F., Rimoldi D., Guillaume P.M., Meidenbauer N., Mackensen A., et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004, 64:2865-2873.